atogepant
Qulipta
Pharmaceutical company: AbbVie
INDICATION & DOSAGE
Prevention of chronic migraine headaches
Children: 60 mg PO once daily.
Adjust-a-dose: Avoid use with CYP3A4 inducers and strong CYP3A4 inhibitors. If used concomitantly with an OATP inhibitor, give 30 mg PO once daily. Avoid use in patients with creatinine clearance less than 30 mL/minute.
Released: June 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer